LifeStance Health Group, Inc. Stock

Equities

LFST

US53228F1012

Healthcare Facilities & Services

Market Closed - Nasdaq 04:00:00 2024-05-10 pm EDT 5-day change 1st Jan Change
6.86 USD -3.65% Intraday chart for LifeStance Health Group, Inc. +3.00% -12.39%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2024 * 1.22B Sales 2025 * 1.38B Capitalization 2.62B
Net income 2024 * -89M Net income 2025 * -76M EV / Sales 2024 * 2.27 x
Net Debt 2024 * 137M Net Debt 2025 * 114M EV / Sales 2025 * 1.99 x
P/E ratio 2024 *
-28.5 x
P/E ratio 2025 *
-31.8 x
Employees 6,866
Yield 2024 *
-
Yield 2025 *
-
Free-Float 26%
More Fundamentals * Assessed data
Dynamic Chart
LifeStance Health Q1 Loss Narrows as Revenue Increases; 2024 Revenue Outlook Reiterated MT
LifeStance Health Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
LifeStance Health Group, Inc. Announces Resignation of Danish Qureshi as President and Chief Operating Officer, Effective June 30, 2024 CI
Earnings Flash (LFST) LIFESTANCE HEALTH Posts Q1 Revenue $300.4M, vs. Street Est of $299M MT
LifeStance Health Group, Inc. Provides Earnings Guidance for the Second Quarter of 2024; Reiterates Earnings Guidance for the Full Year of 2024 CI
LifeStance Health Appoints Teresa DeLuca to Its Board of Directors CI
Jefferies Adjusts Price Target on LifeStance Health to $9 From $8, Maintains Buy Rating MT
Lifestance Health Group Insider Sold Shares Worth $923,391, According to a Recent SEC Filing MT
Goldman Sachs Adjusts Price Target on LifeStance Health to $9 From $8, Maintains Neutral Rating MT
UBS Adjusts LifeStance Health Group Price Target to $9 From $7, Maintains Neutral Rating MT
Barclays Adjusts LifeStance Health Group Price Target to $8 From $7, Maintains Underweight Rating MT
Sector Update: Health Care Stocks Decline Late Afternoon MT
Sector Update: Health Care Stocks Softer Wednesday Afternoon MT
LifeStance Health Q4 Loss Narrows as Revenue Increases; Shares Rise MT
LifeStance Health Q4 Loss Narrows as Revenue Increases; Shares Rise MT
More news
1 day-3.65%
1 week+3.00%
Current month+11.00%
1 month+11.73%
3 months+3.31%
6 months+22.28%
Current year-12.39%
More quotes
1 week
6.68
Extreme 6.68
7.40
1 month
5.62
Extreme 5.615
7.40
Current year
4.74
Extreme 4.735
9.20
1 year
4.74
Extreme 4.735
9.59
3 years
4.22
Extreme 4.22
29.81
5 years
4.22
Extreme 4.22
29.81
10 years
4.22
Extreme 4.22
29.81
More quotes
Managers TitleAgeSince
Founder 39 16-12-31
Chief Executive Officer 65 22-09-06
Director of Finance/CFO 55 22-11-09
Members of the board TitleAgeSince
Chief Executive Officer 65 22-09-06
Director/Board Member 50 16-12-31
Director/Board Member 51 16-12-31
More insiders
Date Price Change Volume
24-05-10 6.86 -3.65% 1,318,182
24-05-09 7.12 +2.01% 1,973,541
24-05-08 6.98 0.00% 1,920,775
24-05-07 6.98 +1.01% 1,223,973
24-05-06 6.91 +3.75% 890,896

Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT

More quotes
LifeStance Health Group, Inc. is a mental healthcare company. The Company is focused on providing of virtual and in-person outpatient mental health care for children, adolescents and adults experiencing a variety of mental health conditions. Its clinicians provide services spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The Company treats a broad range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. It uses evidence-based approaches to ensure effective treatment. The Company offers patients the ability to conduct a given visit with their clinician virtually. It has around 6,645 employed psychiatrists, APNs, psychologists, and therapists. It employs approximately 6,600 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 33 states and more than 550 centers.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
6.86 USD
Average target price
8.786 USD
Spread / Average Target
+28.07%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW